Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 4, 2016, Pages 710-720

  Bonelli, Michael ^a   Göschl, Lisa ^a   Blüml, Stephan ^a   Karonitsch, Thomas ^a   Hirahara, Kiyoshi ^b   Ferner, Elisabeth ^a   Steiner, Carl Walter ^a   Steiner, Günter ^a   Smolen, Josef S ^a   Scheinecker, Clemens ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Abatacept; CTLA 4Ig; Foxp3; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; L SELECTIN;

AGED; APOPTOSIS; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84963744155     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev403     Document Type: Article

References (41)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:195-9.
3. Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Front Biosci 2001;6:D1369-78.
4. Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res Ther 2008;10:S3.
5. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
6. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
7. Alegre ML, Frauwirth KA, Thompson CB. Tcell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220-8.
8. Leibson PJ. The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol 2004;16:328-36. PubMed PMID: 15134782.
9. Sansom DM, Hall ND. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur J Immunol 1993;23:295-8.
10. Azuma M, Yssel H, Phillips JH, Spits H, Lanier LL. Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med 1993;177:845-50.
11. Jeannin P, Herbault N, Delneste Y et al. Human effector memory T cells express CD86: a functional role in naive T cell priming. J Immunol 1999;162:2044-8.
12. + T cells. J Immunol 2012;188:1620-9.
13. Taylor PA, Lees CJ, Fournier S et al. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 2004;172:34-9.
14. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 2004;101:10398-403.
15. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
16. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71.
17. Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebocontrolled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
18. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-23.
19. + T cells. Eur J Immunol 1996;26:1700-6.
20. Nakada M, Nishizaki K, Yoshino T et al. CD80 (B7-1) and CD86 (B7-2) antigens on house dust mite-specific T cells in atopic disease function through T-T cell interactions. J Allergy Clin Immunol 1999;104:222-7.
21. + cells producing cytoplasmic HIV type 1 p24. AIDS Res Hum Retroviruses 1999;15:173-81.
22. + tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000;119:19-27.
23. Kochli C, Wendland T, Frutig K et al. CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett 1999;65:197-201.
24. Liu MF, Kohsaka H, Sakurai H et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 1996;39:110-4.
25. Okamoto T, Saito S, Yamanaka H et al. Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. J Rheumatol 2003;30:1157-63.
26. Wan B, Nie H, Liu A et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50.
27. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. + regulatory T cells are highly susceptible to CD95 ligand-but not to TCRmediated cell death. J Immunol 2005;175:32-6. PubMed PMID: 15972628.
29. Weiss EM, Schmidt A, Vobis D et al. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol 2011;187:1684-91.
30. + regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death. J Immunol 2008;180:8316-26.
31. + regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 2007;67:1291-8.
32. + T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010;70:2686-96.
33. Yin XM, Wang K, Gross A et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886-91.
34. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011;31:588-95.
35. Pieper J, Herrath J, Raghavan S et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013;14:34.
36. Picchianti DA, Rosado MM, Scarsella M et al. Abatacept (CTLA4-Ig) improves B cell function and Treg inhibitory capacity in rheumatoid arthritis patients non responding to anti-TNF-α agents. Clin Exp Immunol 2014;177:630-40.
37. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13.
38. Boissier MC, Assier E, Biton J et al. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009;76:10-4.
39. Pandiyan P, Gartner D, Soezeri O et al. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med 2004;199:831-42.
40. + regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
41. + regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. J Exp Med 2000;192:303-10.